NNZ-2591

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Prader-Willi Syndrome

Conditions

Prader-Willi Syndrome

Trial Timeline

Sep 1, 2023 → Jun 30, 2025

NCT ID

NCT05879614

About NNZ-2591

NNZ-2591 is a phase 2 stage product being developed by Neuren Pharmaceuticals for Prader-Willi Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05879614. Target conditions include Prader-Willi Syndrome.

What happened to similar drugs?

0 of 9 similar drugs in Prader-Willi Syndrome were approved

Approved (0) Terminated (1) Active (8)

🔄somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohortPfizerPhase 3

🔄CarbetocinAcadia PharmaceuticalsPhase 3

🔄Carbetocin + PlaceboAcadia PharmaceuticalsPhase 3

🔄DCCRSoleno TherapeuticsPhase 3

🔄DCCR + DCCR + Placebo for DCCRSoleno TherapeuticsPhase 3

🔄PitolisantHarmony BiosciencesPhase 3

🔄Pitolisant tabletHarmony BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05879614	Phase 2	Withdrawn	Sep 1, 2023	Jun 30, 2025	Prader-Willi Syndrome
NCT05025332	Phase 2	Completed	Oct 14, 2022	May 3, 2024	Pitt Hopkins Syndrome
NCT05025241	Phase 2	Completed	Aug 8, 2022	Nov 17, 2023	Phelan-McDermid Syndrome
NCT05011851	Phase 2	Completed	Jul 12, 2022	Jul 16, 2024	Angelman Syndrome

Competing Products

18 competing products in Prader-Willi Syndrome

See all competitors

Product	Company	Stage	Hype Score
Octreotide + Placebo	Novartis	Pre-clinical	18
Norditropin SimpleXx	Novo Nordisk	Pre-clinical	26
somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohort	Pfizer	Phase 3	40
Setmelanotide + Placebo	Rhythm Pharmaceuticals	Phase 2	32
Setmelanotide	Rhythm Pharmaceuticals	Phase 2	36
RGH-706 + Placebo	Richter Gedeon	Phase 2	32
Carbetocin	Acadia Pharmaceuticals	Phase 3	44
Carbetocin + Placebo	Acadia Pharmaceuticals	Phase 3	41
DCCR	Soleno Therapeutics	Phase 3	38
DCCR + DCCR + Placebo for DCCR	Soleno Therapeutics	Phase 3	34
Pitolisant	Harmony Biosciences	Phase 3	41
Pitolisant tablet	Harmony Biosciences	Phase 3	41
Pitolisant oral tablets + Placebo oral tablet	Harmony Biosciences	Phase 2	33
DCCR	Soleno Therapeutics	Phase 3	26
VYKAT XR	Soleno Therapeutics	Pre-clinical	27
DCCR + Placebo for DCCR	Soleno Therapeutics	Phase 3	34
BMB-101 + Placebo	Bright Minds Biosciences	Phase 2	36
ARD-101	Aardvark Therapeutics	Phase 2	25